UT settles Liquidia patent suits: $330.4M inflow, Yutrepia PH-ILD label removal

UNITED THERAPEUTICS Corp

• Liquidia to pay UT $330.4M: $185M within 30 business days for past Yutrepia PH-ILD sales, plus $145.4M in two $72.7M installments due Jan 31 and Apr 30, 2027.
• UT to pay Liquidia $10M to settle the RareGen/Sandoz antitrust case; Liquidia must obtain Sandoz consent to secure dismissal.
• Liquidia must file an FDA amendment stripping the PH-ILD indication from Yutrepia's label, halt PH-ILD promotion/detailing, and end ASCENT PH-ILD trial cohorts.
• Third Circuit on Oct 7, 2026 affirmed UT on antitrust claims, reversed Sandoz's $61.6M breach-of-contract award, and revived the tortious interference claim.
• UT's '327 patent runs to Feb 3, 2042; trade-secret claims against former Liquidia executive Dr. Robert Roscigno survive the settlement.